First Author: M.Siddique UK
Co Author(s): I. Khan M. Musadiq
Back to previous
To evaluate the efficacy and side effects of intravitreal ocriplasmin
Hospital Based, Interventional study
Suitable patients were identified for intravitreal Jetrea. Patients with VMT and stage 2 macular holes were included. ERM was an exclusion. OCT was performed on the day of injection to see if they still need injection or not.
We identified 12 patients out of which 2 settled without injection. Ten patients needed injection and 60 percent got VMT released in 28 days. No side effects were noted.
Ocriplasmin is a good treatment for VMT and stage 2 macular holes.